20.500.12556/DiRROS-29714 Recurrence rate and survival in 260 patients with oncocytic thyroid cancer according to response to initial treatment a single-institution experience Oncocytic thyroid carcinoma (OTC) is a rare disease. There is little information about risk factors for recurrence. The aim of our retrospective, single-institution study was to investigate the recurrence rate in OTC patients with and without an excellent response after initial treatment according to the 2025 American Thyroid Association guidelines response criteria based on type of initial intervention. Material/Methods: Altogether, 260 patients with OTC (57 men, 203 women; mean age 60.35 years; range 16-90 years) treated from 1972 to 2024 were included. Initially, regional and distal metastases were diagnosed in 15 (6%) and 25 (10%) patients, respectively. Cox’s multivariate regression model was used to identify the risk factors for recurrence. Results: The follow-up period ranged from 0.1 to 45.2 (median 7.9) years. Recurrence was diagnosed in 39 (17%) of the 235 patients without disease after initial treatment. Locoregional, distant, and combined locoregional and distant recurrence was diagnosed in 18, 14, and 7 patients, respectively. Among 154 patients with an excellent response, recurrence occurred in 6.5%, and among the 81 patients without an excellent response, it occurred in 36% (P<0.001). Independent risk factors for recurrence were: sex (males, hazard ratio (HR)=2.5, 95% CI 1.3-4.8; P=0.009), age (³55 years, HR=2.7, 95% CI 1.2-5.8; P=0.012), pT stage (pT3 or pT4, HR=1.4, 95% CI 1.0-1.9; P=0.023), and residual tumor after surgery (R1 or R2 residual tumor, HR=1.2, 95% CI 1.07-1.3; P=0.001). The 5-year disease-free survival rate for the entire cohort was 88%, while the 10-year and 20-year disease-free survival rates were 79%, and 74%, respectively. Conclusions: Recurrence rate in patients with and without an excellent response was 6.5% and 35%, respectively. Recurrence was more common in men, older patients, those with regional metastases, and those with residual tumor after surgery prognosis risk factors survival rate thyroid neoplasms napovedni dejavniki dejavniki tveganja stopnja preživetje rak ščitnice true false true Medical Science International Warszawa Angleški jezik Slovenski jezik by Authors Neznano 2026-06-03 13:32:07 2026-06-03 13:32:07 2026-06-04 04:04:44 0000-00-00 00:00:00 2026 0 0 str. e950937-1-e950937-13 Vol. 32 May 2026 0000-00-00 Zaloznikova Objavljeno apc 2025-07-31 2026-02-08 2026-05-04 616.4 1234-1010 10.12659/MSM.950937 277560835 RAZ_Besic_Nikola_2026.pdf RAZ_Besic_Nikola_2026.pdf 1 7C056B9731D72857CA3548363E2FDF50 e4f6882b42d42b841e5c30d32f89d0ebd1c0ef4f7026b6c5e7dd46f1238d7afc 2161290a-5f41-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44645 Onkološki inštitut Ljubljana 0 0 0